Development of an Albumin-Masked mutPD-1Ig as a Tumor Lesion-Selective Immune Checkpoint Inhibitor

[Image: see text] The antitumor effects elicited by immune checkpoint inhibitors (ICIs) have transformed cancer treatments. However, severe immune-related adverse events (irAEs) resulting from these treatments have restricted the application of ICIs. To overcome the adverse events, we developed a tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Chien-Yu, Li, Zhi-Qin, Huang, Hsiao-Chen, Hung, Chung-Heng, Weng, Shun-Long, Tzou, Shey-Cherng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621011/
https://www.ncbi.nlm.nih.gov/pubmed/37929112
http://dx.doi.org/10.1021/acsomega.3c06216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621011/
https://www.ncbi.nlm.nih.gov/pubmed/37929112
http://dx.doi.org/10.1021/acsomega.3c06216

Ejemplares similares